Marie-Noelle Boivin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marie-Noelle Boivin has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Jason Karamchandani
The Neuro-Montreal Neurological Institute- Hospital, McGill University, Montreal, Québec, Canada
2 shared publicationsAbby Snape
Department of Biochemistry and Goodman Cancer Institute, McGill University
1 shared publication- Adam MacDonald
Montreal Neurological Institute-Hospital, McGill University
1 shared publication Agessandro Abrahao
Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
1 shared publicationAlan Evans
The Neuro-Montreal Neurological Institute- Hospital, McGill University, Montreal, Québec, Canada
1 shared publicationAngela Genge
The Neuro-Montreal Neurological Institute- Hospital, McGill University, Montreal, Québec, Canada
1 shared publication
Latest Publications
- Open Access
- 4 December 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20  (12) , e0332430
Comprehensive analysis platform to understand, remedy, and eliminate amyotrophic lateral sclerosis (CAPTURE ALS): Study protocol for a Canadian multicenter, multimodal, longitudinal observational study
Background: The marked heterogeneity of Amyotrophic Lateral Sclerosis (ALS) combined with a lack of biomarkers are key contributing factors to the lack of disease-modifying treatments. The Comprehensive Analysis Platform to Understand Remedy and Eliminate ALS (CAPTURE ALS) is a Canadian platform designed to create the most comprehensive picture of people living with ALS with the objective of facilitating ALS research initiatives worldwide. Objectives: The main aims of CAPTURE ALS include: (1) to characterize ALS and healthy controls with biosamples and data in order to provide the most comprehensive picture of individuals living with ALS to date; (2) to create a de-identified database and biosample repository linked to detailed clinical information; and (3) to develop and implement an inclusive and transparent participant engagement strategy to be active throughout all stages of CAPTURE ALS. Methods/Results: CAPTURE ALS is a prospective, multicenter, observational, longitudinal study. People living with ALS, or a related disease and healthy controls undergo a harmonized protocol including the collection of detailed clinical information, neurological and cognitive examination, speech recording, advanced magnetic resonance imaging, and biosampling. Data and samples are stored in a biobank operating under an open science governance framework. An inclusive and transparent participant engagement strategy was designed and implemented throughout all stages of CAPTURE ALS. Four sites are operating in the consortium with a fifth being onboarded. The target enrollment is 120 affected participants and 50 controls, with the first participant visit having occurred in March 2022. Recruitment is ongoing. Discussion: CAPTURE ALS is a scalable clinical research platform that connects scientists and patients to facilitate efficient translational research. The unique and deeply phenotyped data and biosamples are a global resource towards the development of biomarkers and understanding ALS biology. This study is registered at clinicaltrials.gov (NCT: NCT05204017).
- 4 December 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20  (12) , e0332430
Open AccessComprehensive analysis platform to understand, remedy, and eliminate amyotrophic lateral sclerosis (CAPTURE ALS): Study protocol for a Canadian multicenter, multimodal, longitudinal observational study
Background: The marked heterogeneity of Amyotrophic Lateral Sclerosis (ALS) combined with a lack of biomarkers are key contributing factors to the lack of disease-modifying treatments. The Comprehensive Analysis Platform to Understand Remedy and Eliminate ALS (CAPTURE ALS) is a Canadian platform designed to create the most comprehensive picture of people living with ALS with the objective of facilitating ALS research initiatives worldwide. Objectives: The main aims of CAPTURE ALS include: (1) to characterize ALS and healthy controls with biosamples and data in order to provide the most comprehensive picture of individuals living with ALS to date; (2) to create a de-identified database and biosample repository linked to detailed clinical information; and (3) to develop and implement an inclusive and transparent participant engagement strategy to be active throughout all stages of CAPTURE ALS. Methods/Results: CAPTURE ALS is a prospective, multicenter, observational, longitudinal study. People living with ALS, or a related disease and healthy controls undergo a harmonized protocol including the collection of detailed clinical information, neurological and cognitive examination, speech recording, advanced magnetic resonance imaging, and biosampling. Data and samples are stored in a biobank operating under an open science governance framework. An inclusive and transparent participant engagement strategy was designed and implemented throughout all stages of CAPTURE ALS. Four sites are operating in the consortium with a fifth being onboarded. The target enrollment is 120 affected participants and 50 controls, with the first participant visit having occurred in March 2022. Recruitment is ongoing. Discussion: CAPTURE ALS is a scalable clinical research platform that connects scientists and patients to facilitate efficient translational research. The unique and deeply phenotyped data and biosamples are a global resource towards the development of biomarkers and understanding ALS biology. This study is registered at clinicaltrials.gov (NCT: NCT05204017).
- Open Access
- 7 August 2024
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 7  (10) , e202402755
PPM1G dephosphorylates eIF4E in control of mRNA translation and cell proliferation
The mRNA 5′cap-binding eukaryotic translation initiation factor 4E (eIF4E) plays a critical role in the control of mRNA translation in health and disease. One mechanism of regulation of eIF4E activity is via phosphorylation of eIF4E by MNK kinases, which promotes the translation of a subset of mRNAs encoding pro-tumorigenic proteins. Work on eIF4E phosphatases has been paltry. Here, we show that PPM1G is the phosphatase that dephosphorylates eIF4E. We describe the eIF4E-binding motif in PPM1G that is similar to 4E-binding proteins (4E-BPs). We demonstrate that PPM1G inhibits cell proliferation by targeting phospho-eIF4E–dependent mRNA translation.
- 7 August 2024
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 7  (10) , e202402755
Open AccessPPM1G dephosphorylates eIF4E in control of mRNA translation and cell proliferation
The mRNA 5′cap-binding eukaryotic translation initiation factor 4E (eIF4E) plays a critical role in the control of mRNA translation in health and disease. One mechanism of regulation of eIF4E activity is via phosphorylation of eIF4E by MNK kinases, which promotes the translation of a subset of mRNAs encoding pro-tumorigenic proteins. Work on eIF4E phosphatases has been paltry. Here, we show that PPM1G is the phosphatase that dephosphorylates eIF4E. We describe the eIF4E-binding motif in PPM1G that is similar to 4E-binding proteins (4E-BPs). We demonstrate that PPM1G inhibits cell proliferation by targeting phospho-eIF4E–dependent mRNA translation.
- Open Access
Comparative Analysis of Methods to Reduce Activation Signature Gene Expression in PBMCs
Summary: Preserving the in vivo cell transcriptome is essential for accurate profiling, yet factors during cell isolation including time ex vivo and temperature induce artifactual gene expression, particularly in stress-responsive immune cells. In this study, we investigated two methods to mitigate ex vivo activation signature gene (ASG) expression in peripheral blood mononuclear cells (PBMCs): transcription and translation inhibitors (TTis) and cold temperatures during isolation. Comparative analysis of PBMCs isolated with TTis revealed reduced ASG expression. However, TTi treatment impaired responsiveness to LPS stimulation in subsequent in vitro experiments. In contrast, cold isolation methods also prevented ASG expression; up to a point where the addition of TTis during cold isolation offered minimal additional advantage. These findings highlight the importance of considering the advantages and drawbacks of different isolation methods to ensure accurate interpretation of PBMC transcriptomic profiles. Highlights: Traditional room temperature isolation methods trigger activation signature gene expression in PBMCs, even when rapidly isolated, whereas 4°C isolation methods do not. Transcription and translation inhibitors and cold processing techniques reduce activation signature gene expression via shared mechanisms. PBMCs treated with transcription and translation inhibitors lose responsiveness to external stimuli. Cold isolation methods offer a suitable and inexpensive alternative to mitigate activation signature gene expression in PBMCs.
Open AccessComparative Analysis of Methods to Reduce Activation Signature Gene Expression in PBMCs
Summary: Preserving the in vivo cell transcriptome is essential for accurate profiling, yet factors during cell isolation including time ex vivo and temperature induce artifactual gene expression, particularly in stress-responsive immune cells. In this study, we investigated two methods to mitigate ex vivo activation signature gene (ASG) expression in peripheral blood mononuclear cells (PBMCs): transcription and translation inhibitors (TTis) and cold temperatures during isolation. Comparative analysis of PBMCs isolated with TTis revealed reduced ASG expression. However, TTi treatment impaired responsiveness to LPS stimulation in subsequent in vitro experiments. In contrast, cold isolation methods also prevented ASG expression; up to a point where the addition of TTis during cold isolation offered minimal additional advantage. These findings highlight the importance of considering the advantages and drawbacks of different isolation methods to ensure accurate interpretation of PBMC transcriptomic profiles. Highlights: Traditional room temperature isolation methods trigger activation signature gene expression in PBMCs, even when rapidly isolated, whereas 4°C isolation methods do not. Transcription and translation inhibitors and cold processing techniques reduce activation signature gene expression via shared mechanisms. PBMCs treated with transcription and translation inhibitors lose responsiveness to external stimuli. Cold isolation methods offer a suitable and inexpensive alternative to mitigate activation signature gene expression in PBMCs.